HitchBio

HitchBio is a biotechnology company pioneering a novel therapeutic modality known as RNA-mediated protein degradation. The company's proprietary platform utilizes "Hitch RNAs" (hRNAs), which are bifunctional RNA molecules designed to recruit the cell's endogenous degradation machinery to specific disease-associated proteins. By combining the programmability of RNA with the power of targeted protein degradation, HitchBio aims to address "undruggable" targets that have remained out of reach for traditional small molecules and antibodies. The company is currently focused on developing a pipeline of hRNA therapeutics for applications in oncology, immunology, and other areas with high unmet medical need. HitchBio's modular approach allows for rapid design and optimization of degraders against a wide array of protein targets.